AD

Award Number: W81XWH-€JËËËË HF

TITLE: Üzest  $A' = \frac{1}{2} \frac{$ 

PRINCIPAL INVESTIGATOR: Ö¦ HÓC Ŧ^ a fö \* @[ ,

# CONTRACTING ORGANIZATION: P^}¦^ Á2[ ¦åÁ?^æ¢c@ÂÛ^∙¢^{ Ö^d[ ãdÊ4 CAÁ Ì G€GÁ

REPORT DATE: U&{ à^\Á€€FF

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

R	EPORT DOC	UMENTATIO	N PAGE		Form Approved OMB No. 0704-0188
data needed, and completing a this burden to Department of D 4302. Respondents should be	and reviewing this collection of in befense, Washington Headquart aware that notwithstanding any	formation. Send comments rega ers Services, Directorate for Info	arding this burden estimate or an rmation Operations and Reports n shall be subject to any penalty t	y other aspect of this ( (0704-0188), 1215 Jet for failing to comply wi	rching existing data sources, gathering and maintaining the collection of information, including suggestions for reducing ferson Davis Highway, Suite 1204, Arlington, VA 22202- th a collection of information if it does not display a currently
1. REPORT DATE (DL 01-10-2011	<i>'</i>	2. REPORT TYPE Annual			DATES COVERED (From - To) 21 Sep 2010 - 20 Sep 2011
4. TITLE AND SUBTIT	LE	Annual		5a	CONTRACT NUMBER
Race Treatmen	t and Cardiovas	cular Health: A S	Study of Men Wit	h _	. GRANT NUMBER
Prostate Cance	r				/81XWH-09-1-0731
					PROGRAM ELEMENT NUMBER
6. AUTHOR(S)				5d	. PROJECT NUMBER
Dr. Andrea Cas	sidy-Bushrow			_	
				50	. TASK NUMBER
E-Mail: acassid1@	hfhs.org			5f.	WORK UNIT NUMBER
	GANIZATION NAME(S)	AND ADDRESS(ES)			PERFORMING ORGANIZATION REPORT NUMBER
Henry Ford Hea	•				
Detroit, MI 4820	)2				
	NITORING AGENCY N	AME(S) AND ADDRES	S(ES)	10	. SPONSOR/MONITOR'S ACRONYM(S)
Fort Detrick, Maryl					
				11	. SPONSOR/MONITOR'S REPORT NUMBER(S)
	VAILABILITY STATEN				
13. SUPPLEMENTAR	ic Release; Distribu <mark>Y NOTES</mark>				
treatment type, in p minority men with p men with prostate of Caucasian) have b drawn. However, I a potential gap in C African-American a with ADT. We are medications, and th of African-American <b>15. SUBJECT TERMS</b> Prostate Cancer, s	particular androgen prostate cancer ove cancer, overall and een identified and o ipid monitoring was CVD risk factor mon and Caucasian men now exploring the ne role of additional n and Caucasian pr urvivorship, cardiov	deprivation therapy rall or by treatment by treatment type. over 1200 have bee lacking among thos itoring in a high-risk with prostate cance role of pre- and pos	(ADT). There is a p type. The purpose 2000 prostate cance n abstracted. Overa se ever on ADT, pre group. In our popu er suggesting a need t-diagnosis of hyper factors (e.g. hyperte s.	baucity of dat of this study i er cases (100 all, ~75% of n dominantly in lation, ADT in d for guideline cholesteroler ension, diabe	ease (CVD); this risk is intensified by a exploring the risk of CVD among s to examine race-specific CVD risk in 0 each African American and nen had a post-diagnosis lipid profile the Caucasian group, demonstrating nereased cholesterol levels in both es for regular screening of men treated nia, use of cholesterol-lowering tes) on risk of events in this population
16. SECURITY CLASS			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	UU	11	<b>19b. TELEPHONE NUMBER</b> (include area code)

# **Table of Contents**

# Page

Introduction	4
Body	5
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusion	8
References	10
Appendices	11

# Introduction

Racial differences in the overall health of men living with prostate cancer are an important but understudied area of research. As more men live with their prostate cancer, they face increased risk of cardiovascular disease (CVD) events; this risk is intensified by treatment type. There is a paucity of data exploring the risk of CVD among minority men with prostate cancer overall or by treatment type. As African Americans, in general, are less likely to have CVD risk factors under control and are more likely to experience CVD events, we are (1) examining if African-American men with prostate cancer are more likely to have worsening CVD risk factor profiles and more CVD events than Caucasian men with prostate cancer during a follow-up period of 5 years past diagnosis and (2) examining if androgen deprivation therapy for prostate cancer is associated with worsening CVD risk factor profiles and more CVD events during a follow-up period of 5 years past diagnosis, and to determine whether race modifies these associations. This is a retrospective cohort study of men newly diagnosed with prostate cancer at Henry Ford Health System between years 1998 and 2006. As men undergoing prostate cancer treatment interface with the medical care system, there are considerable opportunities to assess their CVD factor profiles. If African-American men with prostate cancer are more likely to have worsening CVD risk factor profiles and to experience CVD events than their Caucasian counterparts, this could reveal an important and modifiable opportunity to reduce a disparity in the overall health of men with prostate cancer. Although treatment type may be associated with CVD risk factor changes and events, to-date only one study has examined this association in African-Americans. Results from this investigation will be used to identify the need to couple

4

therapy with risk factor monitoring and will stimulate future research into potential underlying causes for these disparities.

### Body

As outlined in the approved statement of work, the following tasks have been completed:

- obtained Human Subjects Regulatory Board Approval;
- obtained and maintained Henry Ford Health System (HFHS) Institutional Review Board Approval for Human Subject Research;
- created Access database for direct medical record abstraction data entry;
- created, piloted and revised medical record abstraction tool;
- created electronic cohort of 2,000 prostate cancer cases (1,000 each African-American and Caucasian);
- developed and implemented quality control procedures;
- on-going database management;
- patient addresses have been geocoded to determine neighborhood-level SES indicators.

A total of >1,200 medical chart abstractions are underway or completed, and a remaining ~700 (~one-third) need to be completed, which places us on track for completion of abstraction within the allotted study period. Data cleaning is on-going, with creation of SAS program files that can be used again once abstraction is completed. Literature reviews are on-going for manuscript preparation and an outline for manuscript I is in the process of being finalized.

As described in the statement of work training activities include completing the following courses: Epid 787 "An Introduction to Multilevel Analysis in Public Health" at the University of

Michigan in July, 2010. This course covered analysis techniques that will be needed for analyzing the geocoded SES variables that are being collected for the current study. The PI also completed the following course: Epid 777 "Geographic Information Systems for Epidemiology" at the University of Michigan in July, 2011, which covered an analytic tool that is key to the SES component of this research. Additionally, the PI has regularly attended the HMORN Cancer Research Network annual meeting. The PI submitted and presented an abstract at the second Innovative Minds in Prostate Cancer Today (IMPaCT) conference (March, 2011) and this poster is included in the appendix.

Preliminary analyses have begun using the electronically obtained data on the cohort of 2,000 men. In cross-sectional studies, Androgen Deprivation Therapy (ADT) is associated with cholesterol levels<sup>1</sup> and ADT may also be associated with worsening risk factor profiles.<sup>2</sup> We examined the relationship of ADT use (ever/never) with total cholesterol level pre- and post-diagnosis (see poster in appendix).

The analytic sample consisted of 2000 prostate cancer cases (1000 each African American and Caucasian) identified from the Henry Ford Health System (HFHS) tumor registry. African-American and Caucasian prostate cancer cases were age (+/- 5 years) and date of diagnosis (+/- 1 year) matched. Information on cholesterol levels 1 year prior to diagnosis to 5 years post-diagnosis and ADT use (ever/never) were obtained from electronic corporate data stores at HFHS. Linear mixed models were fit to examine whether there was a racial difference in cholesterol level, adjusting for first measured cholesterol, by ADT.

A total of 7,528 cholesterol measures were available. Pre-diagnosis, 1077 men (54%) had  $\geq$ 1 cholesterol level measured and post-diagnosis, 1489 men (74%) had  $\geq$ 1 cholesterol level

measured. After diagnosis, there was a racial difference in number of men with cholesterol measures by ADT use (P<0.001); among those ever using ADT, more African-American men had  $\geq 1$  cholesterol measure, while among those never using ADT, more Caucasian men had  $\geq 1$  cholesterol measure. After adjusting for first measured cholesterol, there was evidence for a race by ADT interaction with change in cholesterol level (P=0.06). Compared to Caucasians never on ADT, both Caucasian and African-American men ever on ADT had an increase in cholesterol whereas African-American men never on ADT had a decrease in cholesterol (Table 1).

Table 1: Change in cholesterol level by Androgen Deprivation Therapy (ADT) and race

	C / No ADT	AA / No	C / ADT	AA / ADT	Р-
		ADT			Value
		Est (SE)	Est (SE)	Est (SE)	
Cholesterol	Ref	-1.33 (1.13)	1.64 (1.50)	2.52 (1.52)	0.0661

C, Caucasian; AA, African-American; Est, Estimate; SE, standard error

To our knowledge, this is the first investigation examining change in cholesterol levels by ADT use and race, adjusted for baseline cholesterol levels. Given that the 1-year pre-diagnosis time frame only yielded 54% with a baseline cholesterol level, we obtained IRB approval to obtain the most recent pre-diagnosis cholesterol level not restricting to the 1 year time period, which improves our ability to adjust for baseline cholesterol levels in this cohort. These preliminary analyses are continuing, and we plan to refit our models adjusting for the additional baseline cholesterol levels, as well as CVD medication use and an indicator variable for number of visits with a healthcare provider to our models. In preparation for this, we are in the process of coding our cholesterol medications for use in analysis.

# **Key Research Accomplishments**

• <u>Cholesterol profile of men with prostate cancer varies by race and treatment type</u>. This abstract was submitted and accepted for poster presentation to the IMPACT meeting.

## **Reportable Outcomes**

Cassidy-Bushrow, AE. Mahan, M. Rybicki BA. Cholesterol profile of men with prostate cancer varies by race and treatment type. 2011. Second Innovative Minds in Prostate Cancer Today (IMPaCT) conference, Orlando, FL, March 2010.

# Conclusions

In our study population of men with prostate cancer, most had cholesterol screening at least once within the 5-years post-diagnosis. As demonstrated by others, ADT was associated with an increase in cholesterol level. However, cholesterol monitoring overall was lacking among those ever on ADT, predominantly in the Caucasian group, demonstrating a potential gap in CVD risk factor monitoring in a high-risk group. Given that ADT increased cholesterol levels in both African American and Caucasian men with prostate cancer, guidelines for regular screening of men treated with ADT are warranted. Additional work planned as part of this study includes examination of pre- and post diagnosis of hypercholesterolemia, use of cholesterollowering medications, and the role of additional cardiovascular risk factors (e.g. hypertension, diabetes) on risk of events in this population of African-American and Caucasian prostate cancer cases. Abstraction is continuing and is on-track for completion within the study time frame, with analysis and manuscript preparation on-going in anticipation of completed datasets.

# References

- 1. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. *Int J Impot Res.* 2006;18:494-498.
- Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. *Cancer*. 2008;112:2188-2194.

### Appendices

### Appendix 1. Poster presented at ImPACT meeting

# Cholesterol profile of men with prostate cancer varies by race and treatment type Andrea E. Cassidy-Bushrow, PhD<sup>1</sup>;Meredith Mahan, MS<sup>1</sup>; Benjamín A. Ryhicki, PhD<sup>1,2</sup> <sup>1</sup>Department of Public Health Sciences, Heury Ford Hospital, Detroit, Michigan: <sup>2</sup>Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan

#### Results Tr

- As more men live with their prostate cancer, they face increased risk of cardiovascular disease (CVD)
- Men with prostate cancer have higher noncancer mortality rates than men in the general population
- Increased CVD risk primarily attributable to androgen deprivation therapy (ADT)
- There is a paucity of data examining the risk of CVD among men with prostate cancer within minority groups, both overall and by treatment type
- Lipid profiles, which are powerful predictors of CVD, are not welldescribed in prostate cancer, despite recognition of a need for better quantifying CVD risk before determining treatment type
- The purpose of this investigation was to examine pre- and post-diagnosis lipid profiles among men with prostate cancer, by race and ADT use

#### Study Populat

- Prostate cancer cases diagnosed between 1998 and 2006 were identified from the Henry Ford Health System (HFHS) tumor registry
- Eligibility:
  - Diagnosis and initial treatment at HFHS
    Caucasian or African-American race
  - Caucasian or African-American race
- African American and Caucasian cases were matched by age at diagnosis (±5 years) and year of diagnosis (±1 year): the analytic sample contained 2000 cases (1000 each race)

### Data

- The HFHS corporate data store system (CDS), a central repository for data on all patient encounters at Henry Ford Hospital and HFHS satellites, was used to obtain:

   all available lipid laboratory values pre-diagnosis and up to 5-years
  - all available lipst laboratory values pre-dia post-diagnosis
  - ADT
  - Charlson comorbidity score at diagnosis
- · A PC interface is used to access the various databases of CDS using
- Structured Query Language
- · ADT was defined as ever/never

#### italimical Analyses

- Chi-square tests were used to examine racial difference in prevalence of pre- and post-diagnosis cholesterol screening
- Linear mixed models were fit to examine racial differences in change in cholesterol level, adjusting for first measured cholesterol, by ADT


- African-American men had a greater mean Charlson score, whereas Caucasian men tended toward worse AJCC stage at diagnosis (Table 1)
   More Caucasian than African-American men had pre-diagnosis (P=0.01)
- and post-diagnosis (P=0.06) lipid profiles drawn (Figure 1) • There was a significant race by treatment type difference in post-diagnosis
- lipid testing ( $P^{e}(0.01)$  (Figure 2)
- After adjusting for first measured cholesterol, there was evidence for a race by ADT interaction with change in cholesterol level (P=0.06); compared to Caucasians never on ADT, both Caucasian and African-American men ever on ADT had an increase in cholesterol, whereas African-American men never on ADT had a decrease in cholesterol (Table 2).

#### Table 1. Description of study population

Factor at time of diagnosis	N	African American	Caucasian	P	
Age (years)	2000	67.3 (10.0)	68.2 (9.2)	0.07	
AJCC Stage	1801				
a second and the second se		4 (0.4%)	4 (0.5%)	<0.01	
1	1	787 (86.4%)	731 (82.1%)		
	1	80 (8.8%)	71 (8.0%)		
IV		40 (4.4%)	84 (9.4%)		
Charlson score	1963	3.4 (1.8)	3.0 (1.5)	<0.01	
PSA (ng/ml)	1804	7.0	5.6	0.41	


Data are mean (std) or n (%); PSA is median PSA


#### Figure 1, Race-specific percentage of men with pre- and post-diagnosis lipids



#### 🗉 African American 🗉 Caucasian

	Caucasian/ No ADT	African American/ No ADT	Caucasian/ ADT	African American/ ADT	P
Cholesterol (mg/dl)	Ref	-1.33 (1.13)	1.64 (1.50)	2.52 (1.52)	0.06
HDL (mg/dl)	Ref	-0.29 (0.33)	-0.61 (0.43)	0.32 (0.44)	0.29
LDL (mg/dl)	Ref	0.06 (0.98)	-0.82 (1.32)	2.53 (1.31)	0.18
Triglycerides (mg/dl)	Ref	-113 (2.4)	5.6 (3.1)	-2.92 (3.2)	<0.01





- In this population of men with prostate cancer, most had cholesterol screening at least once within the 5-years post-diagnosis
- As demonstrated by others, ADT was associated with an increase in cholesterol level
- Cholesterol monitoring overall was lacking among those ever on ADT, predominantly in the Caucasian group, demonstrating a potential gap in CVD risk factor monitoring in a high-risk group
- Additional work planned as part of this study includes examination of preand post-diagnosis of hypercholesterolemia, use of cholesterol-lowering medications, and the role of additional cardiovascular risk factors (e.g. hypertension, diabetes) on risk of events in this population of African-American and Caucasian prostate cancer cases

- In this patient sample, nearly 75% of men diagnosed with prostate cancer had at least 1 cholesterol measure after cancer diagnosis, however, particularly among men at increased risk of CVD due to ADT, lipid testing rates can be improved
- Given that ADT increased cholesterol levels in both African-American and Caucasian men with prostate cancer, guidelines for regular screening of men treated with ADT are warranted

#### Acknowledgements

 This work was supported by the Department of Defense, Congressionally Directed Medical Research Programs, award number W81XWH-09-1-0731

### 11